Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Clinical safety

Topic: Risk, prevention and care in population studies

Plain-language summary

Delirium is the most common neuropsychiatric syndrome encountered by clinicians caring for critically ill patients and is best characterized by five core domains: cognitive deficits, attentional deficits, circadian rhythm dysregulation, emotional dysregulation, and alteration in psychomotor functioning. Its occurrence is associated with increased morbidity, increased cost of care and prolonged hospital stays, an increased rate of cognitive disorders, including early onset dementia, and higher mortality rates. This article reviews the current understanding of delirium's patho-physiology, risk factors, and clinical implications in the intensive care unit (ICU) setting. The importance of early detection using validated screening tools, the role of nonpharmacological interventions, and the cautious use of pharmacological treatments are discussed. By synthesizing the latest literature, this review aims to provide a comprehensive overview of delirium in ICUs, emphasizing the need for improved recognition and management to enhance patient outcomes.

What this study adds

Evidence grade: Low

This review describes delirium in intensive care as common and linked to longer hospital stays, higher costs, more cognitive disorders including early onset dementia, and higher death rates. It stresses early detection with validated tools, non-drug interventions and cautious use of medication, but reports no cure or prevention for Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Maldonado, J. R. (2025). Nature and Management of Delirium in the Intensive Care Unit. Psychiatric Annals. https://doi.org/10.3928/00485713-20250528-01

Vancouver

Maldonado JR. Nature and Management of Delirium in the Intensive Care Unit. Psychiatric Annals. 2025. doi:10.3928/00485713-20250528-01.

BibTeX

@article{maldonado2025-04f2084b,
  author  = {Maldonado, José R.},
  title   = {{Nature and Management of Delirium in the Intensive Care Unit}},
  journal = {Psychiatric Annals},
  year    = {2025},
  doi     = {10.3928/00485713-20250528-01},
  url     = {https://doi.org/10.3928/00485713-20250528-01}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review describes delirium in intensive care as common and linked to longer hospital stays, higher costs, more cognitive disorders including early onset dementia, and higher death rates. It stresses early detection with validated tools, non-drug interventions and cautious use of medication, but reports no cure or prevention for Alzheimer's disease.

Study details

How this study scored 35/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 3 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 1 of 2; Free to read 0 of 2. Total 35 of 100.35 of 100 points earned65 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Psychiatric Annals)
Journal's citation record 1 / 4 Psychiatric Annals: journal h-index 83 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 3 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.0 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 2.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author José R. Maldonado: h-index 29 (OpenAlex, whole career)
Institution's track record 3 / 3 Stanford University: institution h-index 2,684 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 0 / 2 Behind a paywall — scores zero
Total 35 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Clinical safety from nearby years

Also tagged “palliative”

858 studies in the library carry the topic tag “palliative”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 858 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Clinical safety

See all studies in Clinical safety →